GRI Bio, Inc.
GRI
$1.51
-$0.02-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.13M | 1.00M | 1.38M | 962.00K | 980.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 0.00 |
| Total Operating Expenses | 1.95M | 2.13M | 2.26M | 1.90M | 2.03M |
| Operating Income | -1.95M | -2.13M | -2.26M | -1.90M | -2.03M |
| Income Before Tax | -5.81M | -2.12M | -2.25M | -1.89M | -2.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.81M | -2.12M | -2.25M | -1.89M | -2.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.81M | -2.12M | -2.25M | -1.89M | -2.00M |
| EBIT | -1.95M | -2.13M | -2.26M | -1.90M | -2.03M |
| EBITDA | -1.95M | -2.13M | -2.26M | -1.89M | -2.03M |
| EPS Basic | -7.86 | -11.42 | -83.56 | -101.04 | -119.08 |
| Normalized Basic EPS | -2.48 | -7.14 | -52.23 | -63.15 | -- |
| EPS Diluted | -15.72 | -11.42 | -83.56 | -101.04 | -119.08 |
| Normalized Diluted EPS | -2.48 | -7.14 | -52.23 | -63.15 | -- |
| Average Basic Shares Outstanding | 491.00K | 185.90K | 26.90K | 18.70K | -- |
| Average Diluted Shares Outstanding | 491.00K | 185.90K | 26.90K | 18.70K | 18.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |